Golcadomide and Rituximab for Relapsed Mantle Cell Lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs (golcadomide and rituximab) for mantle cell lymphoma that has returned or stopped responding to previous treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with mantle cell lymphoma that has returned or stopped responding to at least one prior treatment, including a BTK inhibitor drug
- You are at least 18 years old and in relatively good overall health (ECOG score of 2 or better)
- Your blood cell counts and liver/kidney function are adequate: neutrophils >1,000–1,500/mm³, platelets >50,000–75,000/mm³, and normal liver and kidney tests
- You are negative for HIV, hepatitis B, and hepatitis C
- You can swallow pills and commit to the study schedule and procedures
- If you can become pregnant, you must use two forms of birth control during and for 28 days after treatment, and have negative pregnancy tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
This trial tests a combination of medicines to treat newly diagnosed high-risk mantle cell lymphoma (MCL). It may help shrink the lymphoma and improve outcomes, especially for people whose disease has higher-risk features.
This trial tests a new combination of two drugs, nemtabrutinib (a targeted pill) and rituximab (an antibody infusion), for people with mantle cell lymphoma (MCL) who haven't had prior treatment. The goal is to see how well these drugs work together to control the lymphoma.
This trial tests a combination of two drugs, glofitamab and lenalidomide, for people with mantle cell lymphoma that has come back or not responded to treatment. It's for those with high-risk features, like a fast-growing lymphoma or resistance to previous therapies.
This trial tests a combination of three drugs (glofitamab, ibrutinib, and obinutuzumab) for people with untreated mantle cell lymphoma. The goal is to see if this combination works better for high-risk or older patients.
This trial tests a new drug, Golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or hasn't responded to prior treatment. The goal is to see if this combination works better than other treatments your doctor might choose.
Hear when a new Recurrent Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.